Cerus Corporation
A blood-safety company based in Concord, California, Cerus makes the INTERCEPT Blood System, a technology used by blood banks to zap donated platelets and plasma with UV light and a compound called amotosalen, neutralizing viruses, bacteria, and parasites before they reach patients. Founded in 1991 by hematologist Laurence Corash and chemist John Hearst, the company spun off its immunotherapy business in 2007 to focus on blood safety. Its product is aptly named: the system "intercepts" pathogens by cross-linking their DNA so they can't reproduce, rather than just screening for known ones.
Granted 6.84M · Bought 58.8K · Sold 1.80M
Granted 1.55M · Bought 710.2K · Sold 125.4K
Granted 2.28M · Sold 640.2K
Granted 2.20M · Sold 1.05M
Granted 1.04M · Sold 410.2K
Granted 1.91M · Sold 1.13M
Granted 986.8K · Sold 493.4K
Granted 1.00M · Sold 612.7K
Granted 296.0K · Bought 44.1K
Granted 19.7K · Bought 100.0K
Granted 264.0K · Bought 4.4K
Granted 257.1K · Bought 45.0K · Sold 40.5K
Granted 224.8K · Bought 7.5K
Granted 337.4K · Bought 9.6K · Sold 137.2K
Granted 303.2K · Bought 8.5K · Sold 50.4K
Granted 201.5K · Bought 3.6K
Granted 189.9K · Bought 2.5K
Granted 65.7K · Bought 60.0K
Granted 308.5K · Bought 9.8K · Sold 154.9K
Granted 111.8K · Bought 20.0K
Granted 120.0K · Bought 26.7K
Granted 10.1K
Granted 20.9K
Granted 26.8K · Sold 1.4K
Granted 100.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Greenman William MarinerPresident and CEO, Director · 85 transactions | — | 5.00M | 6.84M | 58.8K | 1.80M |
| Corash Laurence MChief Scientific Officer · 121 transactions | — | 2.34Mas of Mar 2024 | 1.55M | 710.2K | 125.4K |
| Jayaraman Vivek KChief Operating Officer · 55 transactions | — | 1.66M | 2.28M | — | 640.2K |
| Green Kevin DennisChief Financial Officer · 98 transactions | — | 1.24M | 2.20M | — | 1.05M |
| Jensen ChrystalChief Legal Officer · 19 transactions | — | 1.15M | 1.04M | — | 410.2K |
| Benjamin Richard JChief Medical Officer · 79 transactions | — | 777.4K | 1.91M | — | 1.13M |
| Menard ChrystalChief Legal Officer · 66 transactions | — | 509.5Kas of Mar 2024 | 986.8K | — | 493.4K |
| Moore CarolSVP Reg. & Quality · 60 transactions | — | 501.0Kas of Mar 2024 | 1.00M | — | 612.7K |
| Witney FrankDirector · 13 transactions | — | 340.1K | 296.0K | 44.1K | — |
| Cassin BJDirector · 7 transactions | — | 337.2Kas of Nov 2013 | 19.7K | 100.0K | — |
| Nachtsheim Jami KDirector · 12 transactions | — | 268.4K | 264.0K | 4.4K | — |
| Bjerkholt EricDirector · 15 transactions | — | 261.7K | 257.1K | 45.0K | 40.5K |
| Lucena AnnDirector · 6 transactions | — | 232.3K | 224.8K | 7.5K | — |
| Anderson Timothy BDirector · 32 transactions | — | 214.0Kas of Jun 2021 | 337.4K | 9.6K | 137.2K |
| Swisher Daniel N JRDirector · 23 transactions | — | 207.0Kas of Jun 2025 | 303.2K | 8.5K | 50.4K |
| Moore Timothy L.Director · 11 transactions | — | 205.1Kas of Jun 2025 | 201.5K | 3.6K | — |
| Shan HuaDirector · 5 transactions | — | 192.4K | 189.9K | 2.5K | — |
| Glassell ClaesExecutive Officer and Director, Director · 8 transactions | — | 189.5Kas of Jan 2011 | 65.7K | 60.0K | — |
| Schulze GailDirector · 22 transactions | — | 163.4Kas of Jun 2024 | 308.5K | 9.8K | 154.9K |
| Dawson William JChief Financial Officer · 14 transactions | — | 156.8Kas of Mar 2008 | 111.8K | 20.0K | — |
| Gregory Dean A.Director · 4 transactions | — | 146.7K | 120.0K | 26.7K | — |
| Cook David NVice President, R & D · 3 transactions | — | 43.8Kas of Jan 2007 | 10.1K | — | — |
| Ervin Howard GVice President, Legal Affairs · 7 transactions | — | 42.8Kas of Jan 2013 | 20.9K | — | — |
| Cozadd Bruce CDirector · 12 transactions | — | 18.9Kas of Jun 2017 | 26.8K | — | 1.4K |
| Hogeboom Caspar JanPresident, Cerus Europe · 7 transactions | — | 10.0Kas of Dec 2015 | 100.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -5.54M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.